Article | May 25, 2017

Lonza and Atvio Biotech Seek New Technologies To Advance Personalized Medicine

Source: Finesse, part of Thermo Fisher Scientific
Lonza and Atvio Biotech Seek New Technologies To Advance Personalized Medicine

Despite their potential to increase the efficiency of the healthcare system, autologous cell therapy treatments present significant challenges to most companies when it comes to development and manufacturing. Innovators across the industry who want to see personalized medicine, such as autologous cell therapies, reach its full potential are focusing on developing technology that can create a realistic business model for these treatments.

Finesse, part of Thermo Fisher Scientific